Is there transparency in the pricing of medicines in the South African private sector
Recent investigations by the Competition Commission of South Africa (SA) of suspected excessive pricing of cancer medicines in SA by three global pharmaceutical companies have once again drawn attention to increasing medicine pricing transparency and warrant further public debate.
Main Authors: | V Bangalee, F Suleman |
---|---|
Format: | Article |
Language: | English |
Published: |
Health and Medical Publishing Group
2018-02-01
|
Series: | South African Medical Journal |
Online Access: | http://www.samj.org.za/index.php/samj/article/download/12200/8381 |
Similar Items
-
Cost-savings accruable to removing value added tax from antiretrovirals in the South African private health sector
by: Varsha Bangalee, et al.
Published: (2017-10-01) -
Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa
by: Phyllis Ocran Mattila, et al.
Published: (2021-07-01) -
Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa?
by: Varsha Bangalee, et al.
Published: (2016-10-01) -
Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa?
by: Varsha Bangalee, et al.
Published: (2016-12-01) -
An analysis of the impact of generic medicine reference pricing in a sector of the South African private healthcare insurance industry
by: Noble-Luckhoff, Jennifer Anne
Published: (2016)